Background. -The implementation of international guidelines for antithrombotic use in atrial fibrillation (AF) in routine practice is not well known, particularly, in some parts of the world, such as the Middle East and Africa. Aim. -To describe and analyse the use of antithrombotics in patients with AF in routine practice.
Background
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, affecting 1-2% of the general population [1, 2] .
A crucial aspect of AF management is the prevention of stroke, using antithrombotic therapy (anti-platelets and oral anticoagulants [OACs] ) [1] [2] [3] [4] . Although international guidelines provide simple rules for the use of antithrombotics in patients with AF, the implementation of these guidelines in routine practice around the globe, particularly outside Europe and North America, is not well known [3, [5] [6] [7] [8] .
The real-life global survey evaluating patients with AF (RealiseAF) survey was established to investigate patient characteristics, cardiovascular risk, types of AF, symptoms and medical history and management practices, including the use of antithrombotics [9] , in routine clinical practice, across a broad range of geographic settings worldwide. The present analysis aimed to describe the use and determinants of use of antithrombotic agents in patients with AF in the regions participating in the RealiseAF survey.
Methods Design
As previously reported, RealiseAF was a cross-sectional observational survey that enrolled 10,546 patients with AF at 831 sites in 26 countries, from October 2009 to May 2010 [9] .
Patients
To be eligible for enrolment, patients had to have a history of AF (treated or untreated), with at least one AF episode documented by standard electrocardiogram or Holter electrocardiogram in the last 12 months, or documented current AF. Exclusion criteria included mental disability, inability to provide written informed consent, AF occurring within 3 months of cardiac surgery, and participation in clinical trials in the AF or antithrombotic field in the previous month. All patients provided written informed consent. Participating physicians were randomly selected from physician list forms [9] . Twenty-six countries from four continents participated in the survey (Appendix A).
Objectives
The main objectives of the present analysis were to describe the use of antithrombotic agents among the RealiseAF patients as a function of the CHADS 2 score (Congestive heart failure, Hypertension, Age > 75 years, Diabetes mellitus and Stroke or transient ischaemic attack [2 points]); to assess compliance with the 2006 American College of Cardiology (ACC)/American Heart Association (AHA)/European Society of Cardiology (ESC) guidelines (which are relevant to patients enrolled between 2009 and 2010) [3] ; and to analyse the results according to geographic region and type of AF (paroxysmal, persistent or permanent). In this analysis, the CHADS 2 score was also calculated in patients with valvular disease.
Statistical analyses
Details of how the sample size was determined have been described previously [9] . Population characteristics were summarized by means ± standard deviations for continuous variables and by counts (percentages) for qualitative variables. Comparisons between subgroups were made using the chi 2 test or analysis of variance as appropriate. To identify factors associated with use of OACs in AF patients with a CHADS 2 score ≥ 2, a multivariable stepwise logistic regression was performed, using a P value of 0.05 to retain the variable in the model. Variables tested were: age by class; obesity; hypertension; left ventricular hypertrophy; history of heart failure by New York Heart Association class; history of coronary artery disease; history of cerebrovascular disease; history of valvular heart disease; type of AF; time since AF diagnosis by class; AF management strategy chosen before the enrolment visit; major bleeding leading to hospitalization in the last 12 months; stroke leading to hospitalization in the last 12 months; and speciality of physician and practice (public/private). Discrimination was assessed using c-statistics and calibration was assessed using Hosmer-Lemeshow statistics. The odds ratios and associated 95% confidence intervals for the use of OACs were determined. Multivariable analysis was adjusted for country. Analyses were performed using SAS ® statistical software, version 9.2 (SAS Institute, Cary, NC, USA).
Results

Participating physicians
A total of 831 physicians participated in the survey. Among these, information regarding speciality was available for 803. The majority were cardiologists (667/803; 83.1%), while around 1 in 10 were internists (63/803; 7.8%) or reported both specialities (cardiologist and internist, 73/803; 9.1%).
Patient characteristics
Of the 10,546 patients enrolled, 10,523 constituted the analysed population. Twenty-three patients were ineligible, due to no history of AF (n = 6), mental illness (n = 1), post-cardiac surgery AF (n = 1), clinical trial in AF or antithrombotic treatment in the previous month (n = 3) or other reasons (n = 14) (one patient had three reasons for ineligibility). Patients had a mean age of 66.6 ± 12.2 years and 56.4% were male. AF was paroxysmal in 24.8%, persistent in 22.3% and permanent in 46.4% of patients; the remaining 6.4% had their first episode of AF, thereby, preventing assignation to one of the previous categories.
Among the RealiseAF population, 12.5% of the patients had a CHADS 2 score of 0, 27.9% had a score of 1 and 59.6% had a score of ≥ 2. Consistent with the elements constituting the score, the population of patients with a CHADS 2 score ≥ 2 was older, had a higher prevalence of cardiovascular risk factors, particularly diabetes and hypertension, and was more likely to have permanent AF and heart failure ( Table 1) . Patient characteristics according to region and type of AF are presented in Tables 2 and 3 .
Use of OACs according to CHADS 2 score
There was an important discrepancy between guideline recommendations [3] and actual use of antithrombotics as a function of the CHADS 2 scores (Fig. 1) . In 46.0% of the patients with a CHADS 2 score of 0, OACs were prescribed. This varied depending on the type of AF, with 23.5%, 52.8% Data are mean ± standard deviation or %; AF: atrial fibrillation; BMI: body mass index; CHADS 2 : Congestive heart failure, Hypertension, Age > 75 years, Diabetes mellitus and Stroke or transient ischaemic attack (2 points); HF: heart failure; NYHA: New York Heart Association; PCI: percutaneous coronary intervention.
and 56.4% of the patients with paroxysmal, persistent and permanent AF, respectively, with a CHADS 2 score of 0, prescribed OACs. However, OACs were not prescribed in 47.4% of the patients with a CHADS 2 score ≥ 2 ( Fig. 1 ). While guidelines would have recommended the use of anti-platelet agents in patients with a CHADS 2 score of 0, only 24.8% of the patients received appropriate anti-platelet therapy. Furthermore, a consistent finding across the CHADS 2 score categories was the substantial proportion of patients not receiving any antithrombotic treatment, ranging from 29.2% in patients with a CHADS 2 score of 0, to 25.7% in patients with a CHADS 2 score of 1 and 19.1% in patients with a CHADS 2 score of ≥ 2.
Geographical differences
In this analysis, patients with AF from the Middle East and Africa were significantly younger and more frequently female compared with those originating from the rest of the world (Table 2) . A CHADS 2 score ≥ 2 was observed in 64.2% of the patients originating from Europe versus 58.3%, 57.8% and 43.6% from Latin America, Asia and the Middle East and Africa, respectively. Among those patients with a CHADS 2 score ≥ 2, there were also important geographical differences with respect to the use of antithrombotics: the proportion of patients not receiving any antithrombotic therapy ranged from 11.4% in the Middle East and Africa to 27.6% in Latin America. Conversely, the use of OACs was highest in the Middle East and Africa (66.7%) and lowest in Asia (31.7%) (Fig. 2) .
Use of antithrombotics according to type of AF
The prescription rate of OACs among patients with a CHADS 2 score ≥ 2 was higher in permanent AF (59.0%) than in paroxysmal and persistent AF (37.7 and 54.4%, respectively). However, the percentage of patients not receiving any antithrombotic therapy in that population was similar in the three groups (17.9%, 20.5% and 19.8%, respectively) ( Fig. 3) . Data are mean ± standard deviation or %; AF: atrial fibrillation; BMI: body mass index; HF: heart failure; NYHA: New York Heart Association; PCI: percutaneous coronary intervention.
Predictors of the use of OACs in AF patients with CHADS 2 score ≥ 2
In AF patients with a CHADS 2 score ≥ 2, a multivariable logistic regression analysis found that the main predictors of OAC use were: age < 75 years; lack of coronary artery disease and major bleeding leading to hospitalization in the last 12 months; presence of persistent/permanent AF (as opposed to paroxysmal); history of valvular disease; presence of stroke leading to hospitalization in the last 12 months; use of a rate control strategy or rhythm control strategy (as opposed to no strategy); and treatment by a cardiologist (as opposed to an internist, Fig. 4 ).
Discussion
In this large international survey, we found that in routine clinical practice, the use of antithrombotics in patients with AF deviates from current guideline recommendations relating to CHADS 2 scores, with both overuse and underuse of OACs reported. This finding is consistent with previous reports in Europe and North America [10] [11] [12] [13] [14] [15] . OACs were not prescribed in 54.0% of the patients with a CHADS 2 score of 0 and 47.4% of patients with a CHADS 2 score ≥ 2 ( Fig. 1) . This is particularly noteworthy considering that OACs are indicated in persistent AF, independent of the CHADS 2 score. While guidelines would have recommended use of anti-platelet agents in patients with a CHADS 2 score of 0, only 24.8% of the patients received appropriate antiplatelet therapy. Even so, this may be due in part to the use of OACs due to cardioversion, which may lead to a reduced percentage of patients receiving anti-platelets. In addition, important differences were observed among geographical regions, with underuse of OACs more frequently observed in the Asian population compared to other geographical areas. However, further studies are required to determine the reasons for these differences. One such study is the ongoing GARFIELD AF registry, an observational prospective study of patients with newly diagnosed AF and additional risk Data are mean ± standard deviation or %; AF: atrial fibrillation; BMI: body mass index; HF: heart failure; NYHA: New York Heart Association; PCI: percutaneous coronary intervention.
factors for stroke. GARFIELD AF aims to enrol 55,000 patients at > 1000 centres in 50 countries, including Argentina, Australia, Brazil, Canada and South Africa [16] . Currently, 27,000 patients are enrolled, and the results are expected to add to our understanding of treatment patterns for stroke prevention in AF across more diverse geographical regions. The implementation of treatment guidelines is complex and various studies have shown that they are only successfully implemented in < 50% of the cases [14, 17] . There are several reasons that may explain the lack of adherence to treatment guidelines observed in this analysis, including: difficulties in extrapolating clinical trial data to patients who may have a complex medical history; lack of awareness; lack of opportunity to evaluate and adapt guidelines to local clinical practice; cultural barriers; psychological factors (e.g. physician fear of bleeding/intracranial haemorrhage); and economic issues (which are particularly apparent in developing countries, where there can be barriers to physicians prescribing effective treatments or accessing monitoring tests [18] ). The lack of international normalized ratio (INR) monitoring in outpatient clinics in some countries or regions and contraindications to OAC use in some patients might also explain the non-adherence to guidelines [19] . Interestingly, the rate of appropriate use of antithrombotics in this analysis was highest in the Middle East and Africa, which contain some of the poorest regions in the world and where INR monitoring is not readily available.
Risk scores in stroke and treatment guidelines must be simple and consistent to avoid confusion among clinicians and non-uniform use of anticoagulation therapy [18, 20, 21] . Variation in the management of patients with AF was found in several reports, not only among physicians [22] , but also among countries. The ADHERE-International registry reported on 2358 patients with AF from 10 Asia-Pacific and Latin American countries; it reported that the highest and lowest rates of OAC use were in Australia (65.2%) and Taiwan (25.1%) [23] . In a large survey from Taiwan including 39,541 patients with AF, only 24.7% of the overall population received appropriate antithrombotic therapy [24] , consistent with the ADHERE findings. Comparable findings were reported in a large survey conducted in the USA [17] . In contrast, in the French EPHA study [25] , as well as in the German AFNET study [26] , OACs were prescribed in a very high proportion of patients (68-93%). Likewise, recent results from the PREFER registry of 7243 patients with AF from Austria, France, Germany, Italy, Spain, Switzerland and the UK showed that OACs were prescribed in 82.3% of the patients [27] . Meanwhile, results from Cohort 1 of 5 in the GARFIELD AF registry (10,614 patients: 27.7% from Asia-Pacific; 2.2% from Canada; 8.1% from Central and South America; and 62.0% from Europe) reported antithrombotic prescription at diagnosis of AF in 60.3% of the patients [28] .
In the present analysis, inappropriate treatment in patients with a CHADS 2 score ≥ 2 was observed more frequently in Asia and Latin America compared with that in Europe and the Middle East and Africa (68.3%, 56.4%, 44.7% and 33.3%, respectively). The reason for such differences is not clear, but there are probably different values and preferences according to region or country regarding the balance of risk and benefit of antithrombotic therapy. The perception of and reported higher propensity for bleeding among Asian patients [29] may explain the reluctance of some physicians to prescribe OACs in Asia compared to those in other regions of the world [29] . It is very likely for that reason that the Japanese guidelines on the management of AF recommend a lower INR control of 1.6-2.6 in patients aged ≥ 70 years [30] , compared with that recommended by the European and American guidelines. In terms of predicting factors for prescribing OACs in patients with a CHADS 2 score ≥ 2, we found that patients who had a previous stroke leading to hospitalization in the last 12 months, permanent or persistent AF, valvular heart disease or who had received treatment by a cardiologist (versus an internist) were most likely to receive OACs. In contrast, older patients aged ≥ 75 years, patients with coronary artery disease and patients with major bleeding events leading to hospitalization in the last 12 months were least likely to receive OACs, despite having a CHADS 2 score ≥ 2. The finding that older patients with AF are less likely to receive OACs has been reported previously [31] [32] [33] . The finding that patients with AF and a CHADS 2 score ≥ 2 who had been cared for by a cardiologist were more likely to receive appropriate antithrombotic treatment than those cared for by an internist has also been observed in previous studies. These include a 2006 study to evaluate the determinants of warfarin use in patients with AF in the USA [34] , and a 2001 study conducted to assess the use of anticoagulation therapy in patients with chronic AF in Taiwan [35] . However, it should be noted that cardiologist care was not identified as a significant factor in a more recent USA meta-analysis aiming to determine the predictors of warfarin use among patients with AF [36] .
In this population, a number of patients had coronary artery disease with an indication for aspirin and/or clopidogrel. The condition might have led physicians to avoid the prescription of OACs, fearing bleeding complications. In fact, withholding OACs in those patients carries a high risk of thromboembolic complications. Hence, there must be a compromise between the risk of bleeding and the risk of thromboembolism. In the most recent 2010 ESC guidelines [6] , a new score that includes a vascular component of CHADS 2 score (Congestive heart failure, Hypertension, Age > 75 years [ proposed to emphasize the importance of considering the associated vascular disease in patients with AF for the determination of the thromboembolic risk [37] . In the same guidelines, a score for the risk of bleeding (HAS-BLED; Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile INR, Elderly, Drugs/alcohol concomitantly) was also proposed [38, 39] . The combination of the two scores allows for better management of these patients.
Limitations
This analysis has some limitations, including the lack of longitudinal follow-up, due to its cross-sectional nature, and a potential for recruitment bias. To minimize the latter, participating physicians were identified at random from a global list of cardiologists and internists (hospitaland office-based). Additionally, the 2006 version of the ACC/AHA/ESC guidelines [3] was used as the evidence base for proper selection of antithrombotic therapy in this analysis, because more recent ESC [6] and American [8] guidelines had not yet been released when the study was conducted. Therefore, the 2006 guidelines constituted contemporary evidence when physicians selected therapy. The 2006 guidelines also recommended the use of the CHADS 2 score for quantifying thromboembolic risk, but this has since been superseded by the CHA 2 DS 2 -VASc score [6] . Nevertheless, as the main focus of this survey was patients with a CHADS 2 score of ≥ 2 (due to their higher risk of thromboembolic events), reanalysis of the data using the CHA 2 DS 2 -VASc score would have added limited value (i.e. these patients would still have been at higher risk for such events). Thus, conclusions regarding antithrombotic use would likely have been similar.
Furthermore, and despite the wide geographical scope of this analysis, it does not include large regions, such as the USA or Central Africa. However, RealiseAF does have unprecedented geographical relevance by including non-white populations and many low-and middle-income countries in the developing world, where the epidemiology and management of AF are less well studied [6] . The inclusion of patients with valvular heart disease in this analysis may also have interfered with the rate of OAC use and may explain, in part, the higher rate of appropriate antithrombotic treatment in countries in the Middle East and Africa, where valvular heart disease is more prevalent. In addition, in those patients with a low CHADS 2 score, the rate of OAC use may have been influenced by the inclusion of patients undergoing cardioversion, in whom OAC use is recommended according to the 2006 ACC/AHA/ESC guidelines [3] . This could unduly lead to the conclusion that OACs are overused in these patients, but such results should be interpreted with caution.
Conclusions
In conclusion, in this large international observational survey, the management of AF deviates from guidelines, with both overuse and underuse of antithrombotic treatment in approximately 50% of the patients, and has important geographical differences. These findings emphasize the need for improved medical education worldwide and for a better understanding of geographical disparities in the implementation of guidelines.
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